TrialBMC cancer2020

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial.

Charlien Berghen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.